Congress funds rare kidney disease research targeting health disparities

What it does

This bill establishes federally funded research centers focused on rare kidney diseases, particularly glomerular diseases, and authorizes studies on early detection and treatment methods. It funds nephrology training programs to increase specialists serving underserved populations, and directs the Secretary of Health and Human Services to study diagnostic testing, treatment patterns, and public awareness strategies for rare kidney disease.

Why we flagged it

The bill's core mechanism is establishing research centers and funding clinical training in nephrology, with supporting studies on diagnostic and treatment methods. It is fundamentally a public health infrastructure and workforce development measure.

What the text implies

• The explicit prohibition on using quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) in cost-effectiveness assessments may signal a broader shift in how NIH-funded research evaluates treatments for rare diseases affecting disabled populations, potentially affecting future research prioritization across other conditions.
• Emphasis on APOL1 gene testing and genetic counseling access may create demand for genetic testing infrastructure and counselor training that currently lacks adequate reimbursement or workforce capacity.
• The study of treatment patterns across Medicare, Medicaid, and private insurance may reveal disparities that could drive future coverage policy changes or payment reform, particularly for dialysis alternatives.

Who it affects

The bill expands research infrastructure and clinical training for a serious, understudied disease affecting vulnerable populations disproportionately. It funds early detection, prevention, and treatment innovation while explicitly protecting disabled individuals from discriminatory cost-effectiveness metrics in research design.

Who stands to gain

• academic medical centers and research institutions
• nephrology training programs
• genetic testing and diagnostic companies
• health professional organizations

Named in the bill

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Centers for Medicare & Medicaid Services (CMS), Health Resources and Services Administration (HRSA), Center for Medicare and Medicaid Innovation (CMMI), Food and Drug Administration (FDA), APOL1 gene, Medicare (Title XVIII), Medicaid (Title XIX)

Where it stands

64 cosponsors: 45 Democrats, 19 Republicans.

• Feb 24, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 24, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 10 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,520,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Gus Bilirakis, the sponsor, reported $937,250 in PAC receipts in the 2026 cycle. $4,000 of that came from 1 PAC tied to these lobbying clients.

• Otsuka America Pharmaceutical, Inc. — $1,240,000 on 1 filing
• Vertex Pharmaceuticals Incorporated — $1,200,000 on 1 filing
• American Kidney Fund — $410,000 on 2 filings
• Travere Therapeutics — $400,000 on 2 filings
• National Kidney Foundation — $140,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.